Manipulation of cytokine networks in transplantation: False hope or realistic opportunity for tolerance?

Transplantation

Volumn 63, Issue 4, 1997, Pages 489-494

  Nickerson, Peter ^a,b   Steiger, Jürg ^a,c   Zheng, Xin Xiao ^a   Steele, Alan W ^a,d   Steurer, Wolfgang ^a,e   Roy Chaudhury, Prabir ^a   Strom, Terry B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e Abt f Transplantationschirugie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE ANTIBODY; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN RECOGNITION; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION;

ANIMALS; CYTOKINES; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031056012     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199702270-00001     Document Type: Review

References (71)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348.
2. Heinzel FP, Sadick MD, Mutha SS, Locksley RM. Production of Interferon γ, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991; 88: 7011.
3. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16: 374.
4. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138.
5. O'Connell PJ, Pacheco-Silva A, Nickerson PW, et al. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993; 150: 1093.
6. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
7. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med 1991; 174: 493.
8. Lipman ML, Stevens AC, Strom TB. Heightened intragraft cytotoxic T lymphocyte gene expression in acutely rejecting renal allografts. J Immunol 1994; 152: 5120.
9. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79.
10. Nickerson P, Zheng X, Steiger J, et al. Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transplant Immunol 1996; 4: 81.
11. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
12. Nickerson PW, Pacheco-Silva A, O'Connell PJ, Steurer W, Rubin Kelley V, Strom TB. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction. Transplant Proc 1993; 25: 984.
13. Bugeon L, Cuturi M-C, Hallet M-M, Paineau J, Chabannes D, Soulillou J- P. Peripheral tolerance of an allograft in adult rats: characterization by low interleukin-2 and interferon-γ mRNA levels and by strong accumulation of major histocompatibility complex transcripts in the graft. Transplantation 1992; 54: 219.
14. Hancock WW, Sayegh MH, Kwok CA, Weiner HL, Carpenter CB. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 1993; 55: 219.
15. Kupiec-Weglinski JW, Wasowska B, Papp I, et al. CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. J Immunol 1993; 151: 5053.
16. Schorle H, Holtschke T, Hünig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991; 352: 621.
17. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155: 489.
18. Minasi LE, Kamogawa Y, Carding S, Bottomly K, Flavell RA. The selective ablation of IL-2 producing cells isolated from transgenic mice. J Exp Med 1993; 177: 1451.
19. Chazen GD, Pereira GMB, LeGros G, Gillis S, Shevach EM. Interleukin 7 is a T cell growth factor. Proc Natl. Acad Sci USA 1989; 86: 5923.
20. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329.
21. Alderson MR, Sassenfeld HM, Widmer MB. IL-7 enhances cytolytic T lymphocyte generation and induces lymphokine activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577.
22. Pattison J, Nelson P, Huie P, et al. RANTES chemokine expression in cell mediated transplant rejection of the kidney. Lancet 1994; 343: 209.
23. Debets R, Savelkoul HFJ. Cytokine antagonists and their potential therapeutic use. Immunol Today 1994; 15: 455.
24. Konieczny BT, Saleem SS, Lowry RP, Lakkis FG. Vigorous cardiac and skin allograft rejection in the absence of IFNγ. J Am Soc Nephrol 1996; 7: 1887.
25. Steiger J, Nickerson P, Ryffel B, Thiel G, Strom TB, Heim M. Islet cell transplantation in IFNγ receptor deficient mice: are Th2 cells upregulated? J Am Soc Nephrol 1996; 7: 1896.
26. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994; 76: 253.
27. Takeshita T, Asao H, Ohtani K, et al. Cloning of the γ chain of the human IL-2 receptor. Science 1992; 257: 379.
28. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science 1993; 262: 1874.
29. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 1993; 262: 1877.
30. Russell SM, Keegan AD, Harada N, et al. Interleukin-2 receptor γ chain: a functional component of the interleukin-4 receptor. Science 1993; 262: 1880.
31. Noguchi M, Yi H, Rosenblatt H, et al. Interleukin-2 receptor g chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73: 147.
32. Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG. Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules. Annu Rev Med 1993; 44: 343.
33. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14: 264.
34. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993; 259: 974.
35. Weiner HL. Oral tolerance. Proc Natl Acad Sci USA 1994; 1994: 10762.
36. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β following antigenic specific triggering. Proc Natl Acad Sci USA 1992; 89: 421.
37. Ruegemer J, Ho S, Augustine J, et al. Regulatory effects of transforming growth factor β on IL2 and IL4-dependent T cell-cycle progression. J Immunol 1990; 144: 1767.
38. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237.
39. Diaz-Gallo C, Moscovitch-Lopatin M, Strom TB, Rubin Kelly V. An anergic, islet-infiltrating T-cell clone that suppresses murine diabetes, secretes a factor that blocks interleukin 2/interleukin 4-dependent proliferation. Proc Natl Acad Sci USA 1992; 89: 8656.
40. Lowry RP. The relationship of IL-4, IL-10, and other cytokines to transplantation tolerance. Transplant Sci 1993; 3: 104.
41. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76(2): 241.
42. Hancock W, Shi C, Picard M, Bianchi C, Russell M. LEW-to-F344 carotid artery allografts: analysis of a rat model of post-transplant vascular injury involving cell-mediated and humoral responses. Transplantation 1995; 60: 1565.
43. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
44. Macatonia SE, Doherty TM, Knight SC, O'Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFNy production. J Immunol 1993; 150: 3755.
45. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915.
46. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferonγ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1042.
47. Ding L, Linsley PS, Huang L-Y, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224.
48. Macatonia SE, Hsieh C-Y, Murphy KM, O'Garra A. Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from αβ TCR transgenic mice: IL-12 substitution from macrophages to stimulate IFN-γ production is IFN-γ-dependent. Int Immunol 1993; 5: 1119.
49. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271.
50. Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528.
51. te Velde AA, Malefijt RdW, Huijbens RJF, de Vries JE, Figdor CG. IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity. J Immunol 1992; 149: 4048.
52. Lee M-S, Wogensen L, Shizuru J, Oldstone MBA, Sarventnick N. Pancreatic islet production of murine interleukin 10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994; 93: 1332.
53. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of non-cytolytic IL-10/Fc in murine models of LPS-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.
54. Qin L, Chavin KD, Ding Y, et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Transplantation 1995; 59: 809.
55. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol 1987; 5: 429.
56. Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol 1994; 152: 5723.
57. Hiester AA, Metcalf DR, Campbel PA. Interleukin-4 is chemotactic for mouse macrophages. Cell Immunol 1992; 139: 72.
58. Masinovsky B, Urdal D, Gallatin WM. IL-4 acts synergistically with IL-1b to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J Immunol 1990; 145: 2886.
59. Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO. Tumor necrosis factor combines with IL-4 or IFNγ to selectively enhance endothelial cell adhesiveness for T cells: the contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991; 146: 592.
60. Piela-Smith TH, Broketa G, Hand A, Korn JH. Regulation of ICAM-1 expression and function in human dermal fibroblasts by IL-4. J Immunol 1992; 148: 1375.
61. Widmer MB, Grabstein KH. Regulation of cytotoxic T-lymphocyte generation by B-cell stimulatory factor. Nature 1987; 326: 795.
62. Widmer MB, Voice RF, Conlon PJ, Grabstein KH. Precursor frequency and lytic specificity of interleukin 2 and interleukin 4-responsive murine lymphocytes. Transplantation 1990; 49: 743.
63. Spits H, Yssel H, Paliard X, Kastelein R, Figdor C, de Vries JE. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 1988; 141: 29.
64. Fanslow WC, Clifford KN, Park LS, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. 1991; 147: 535.
65. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185.
66. Lakkis F, Konieczny BT, Lowry RP, et al. CTLA4Ig induces long-term cardiac allograft survival in the absence of interleukin-4. J Am Soc Nephrol 1996; 7: 1887.
67. Bushell A, Roy-Chaudhury P, Manfro R, et al. IL-4 does not influence the rate of cardiac allograft engraftment: studies in IL-4 knockout mice. J Am Soc Nephrol 1996; 7: 1882.
68. Garside P, Steel M, Worthey EA, et al. T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction. J Immunol 1995; 154: 5649.
69. Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldman H. T cell regulation in adult transplantation tolerance. J Immunol 1996; 157: 529.
70. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 1994; 180: 1587.
71. Arnold B, Schonrich G, Hammerling GJ. Multiple levels of peripheral tolerance. Immunol Today 1993; 14: 12.